H. Ballentine Carter

Author

Johns Hopkins University

Also Known As

H. BALLENTINE CARTER, H. Ballentine Carter, H.Ballentine Carter

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Johns Hopkins Hospital National Institute on Aging Loyola University Maryland Fred Hutch Cancer Center

About

H. Ballentine Carter is an author at Johns Hopkins University specializing in urology, medicine, and biostatistics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	563
2	Biostatistics	5	5	250
3	Public Health	4	4	189
4	Health Sciences	2	2	313
5	Epidemiology	1	1	75

H. Ballentine Carter

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
USE OF REPEAT SEXTANT AND TRANSITION ZONE BIOPSIES FOR ASSESSING EXTENT OF PROSTATE CANCER Jonathan I. Epstein, Patrick C. Walsh, Jurga Sauvageot, The Journal of Urology	1997	192
Prospective Evaluation of Men With Stage T1C Adenocarcinoma of the Prostate H. Ballentine Carter, Jurga Sauvageot, Patrick C. Walsh, The Journal of Urology	1997	184
Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy Jonathan I. Epstein, Harriete Sanderson, H. Ballentine Carter, Urology UrologySurgical OncologySaturation BiopsyMedical ImagingGenitourinary Cancer	2005	166
Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity H. Ballentine Carter, Daniel W. Chan, Jay D. Pearson, Urology	1995	160
Evaluation of Transrectal Ultrasound in the Early Detection of Prostate Cancer H. Ballentine Carter, Ulrike M. Hamper, Sheila Sheth, The Journal of Urology Medical UltrasoundSurgical OncologySurgeryOncologyGenitourinary Cancer	1989	147
Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis H. Ballentine Carter, A. Partin, Albert A. Luderer, Urology	1997	104
Can Prostate Specific Antigen Derivatives and Pathological Parameters Predict Significant Change in Expectant Management Criteria for Prostate Cancer? Masood A. Khan, H. Ballentine Carter, Jonathan I. Epstein, The Journal of Urology	2003	78
Mixed‐effects regression models for studying the natural history of prostate disease Jay D. Pearson, Christopher H. Morrell, Patricia K. Landis, Statistics in Medicine Biomarker (Medicine)UrologyProstate DiseaseNatural HistoryMixed‐effects Regression Models	1994	75
Estimating Unknown Transition Times Using a Piecewise Nonlinear Mixed-Effects Model in Men with Prostate Cancer Christopher H. Morrell, Jay D. Pearson, H. Ballentine Carter, Journal of the American Statistical Association Cancer ResearchPrognostic BiomarkersUrologyCancer EpidemiologyGenitourinary Cancer	1995	68
Prostate-Specific Antigen Velocity Risk Count Assessment: A New Concept for Detection of Life-Threatening Prostate Cancer During Window of Curability H. Ballentine Carter, Anna Kettermann, Luigi Ferrucci, Urology Biomarker (Medicine)UrologyOncologyCancer DetectionMedicine	2007	61

Page 1